We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J to Pay $2.2 Billion to Resolve Risperdal Off-Label Marketing
J&J to Pay $2.2 Billion to Resolve Risperdal Off-Label Marketing
November 11, 2013
In the third-largest healthcare fraud settlement ever, Johnson & Johnson (J&J) and its subsidiaries will pay more than $2.2 billion in criminal and civil fines for off-label promotion of three drugs